Servier and Pieris Pharmaceuticals, a transatlantic biotech company, announced that the first patient has been dosed in the global phase 1/2 study for the treatment of solid tumors.
Pieris is advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications. Proprietary to Pieris, Anticalin® proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships.
The lead molecule of the alliance is a bispecific fusion protein comprising of 4-1BB-targeting Anticalin proteins and a PD-L1-targeting antibody. The global study will evaluate the safety, tolerability, potential optimal dosage, and potential anti-tumor activity of the molecule in patients with advanced solid tumors whose cancer progressed on standard-of-care treatment.
“The dosing of the first patient in this study marks a meaningful step to developing a potential future treatment for cancer patients with limited options,” said Patricia Belissa-Mathiot, Director of Clinical Development and R&D Chief Medical Officer.
Servier and Pieris have been collaborating since 2017 on multiple strategic programs for the research and development of new therapies in immuno-oncology.